FDA — authorised 24 May 2019
- Application: ANDA210318
- Marketing authorisation holder: GLENMARK SPECLT
- Status: supplemented
FDA authorised Asprin on 24 May 2019
Yes. FDA authorised it on 24 May 2019; FDA has authorised it.
GLENMARK SPECLT holds the US marketing authorisation.